AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Cyclacel Plunges 11.09% on Revenue Guidance Cut
Generated by AI AgentAinvest Pre-Market Radar
Monday, Jul 21, 2025 7:07 am ET1min read
Aime SummaryOn July 21, 2025, Cyclacel's stock price dropped by 11.09% in pre-market trading.
Cyclacel Pharmaceuticals, Inc. has seen significant volatility in its stock price, with a one-year low of $3.08 and a one-year high of $597.60. This wide range indicates the speculative nature of the stock, which can be influenced by various factors including market sentiment and company-specific news.
The company's short interest ratio is relatively low, with 1,300 shares shorted, representing 0.08% of the float. This suggests that there is not a significant amount of bearish sentiment among investors, which could be a positive sign for the stock's stability.
Cyclacel's stock price has been influenced by updates to its revenue guidance for the fiscal year 2025. The company's decision to adjust its revenue projections has led to a decline in its stock price, reflecting investor concerns about the company's financial performance.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Esperion Therapeutics shares plunge 5.14% on Dec. 31 2025 due to regulatory and pipeline shifts
Dec.31 2025
Ses AI (NYSE: SES) plunges 6.28% as investors unwind holiday-driven rally gains amid mixed corporate signals.
Dec.31 2025
Novabay Pharmaceuticals Inc (NBY) Surges 27.57% in Pre-Market on December 31 as Small-Cap Biopharma Gains Lead
Dec.31 2025
Dingdong (Cayman) shares plunge 7.09% amid mixed earnings and strategic shifts
Dec.31 2025
Flushing Financial Corp. Plunges 8.94% Amid Renewed Merger Scrutiny
Dec.31 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet